A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Dela Cruz, Filemon; Diolaiti, Daniel; Turk, Andrew; Rainey, Allison; Ambesi-Impiombato, Alberto; Andrews, Stuart; Mansukhani, Mahesh; Nagy, Peter; Alvarez, Mariano; Califano, Andrea; Forouhar, Farhad; Modzelewski, Beata; Mitchell, Chelsey; Yamashiro, Darrell; Marks, Lianna; Bender, Julia; Kung, Andrew
• Is Part Of: Genome medicine. Volume 8:Issue 1(2016)
• Page Start: 1
• Page End: 17
• Publication Date: 2016-12
• Subjects: Poorly differentiated carcinoma (PDC) -- Patient-derived xenograft (PDX) models -- Precision medicine -- MAX -- mTOR -- BRAF -- Temsirolimus -- Whole exome sequencing (WES); Genomics -- Periodicals; Medical genetics -- Periodicals; 616.042
• DOI: 10.1186/s13073-016-0366-0
• Languages: English
• ISSNs: 1756-994X

Abstract

Abstract Background Precision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic, prognostic, and therapeutic value. We describe the clinical case and molecular characterization of an adolescent with metastatic poorly differentiated carcinoma (PDC). Given the rarity and poor prognosis associated with PDC in children, we utilized genomic analysis and preclinical models to validate oncogenic drivers and identify molecular vulnerabilities. Methods We utilized whole exome sequencing (WES) and transcriptome analysis to identify germline and somatic alterations in the patient's tumor. In silico and in vitro studies were used to determine the functional consequences of genomic alterations. Primary tumor was used to generate a patient-derived xenograft (PDX) model, which was used for in vivo assessment of predicted therapeutic options. Results WES revealed a novel germline frameshift variant (p.E1554fs) in APC, establishing a diagnosis of Gardner syndrome, along with a somatic nonsense (p.R790*) APC mutation in the tumor. Somatic mutations inTP53, MAX, BRAF, ROS1, andRPTOR were also identified and transcriptome and immunohistochemical analyses suggested hyperactivation of the Wnt/ß-catenin and AKT/mTOR pathways. In silico and biochemical assays demonstrated that the MAX p.R60Q and BRAF p.K483E mutations were activating mutations, whereas theROS1 andRPTOR mutations were of lower utility for therapeutic targeting. Utilizing a patient-specific PDX model, we demonstrated in vivo activity of mTOR inhibition with temsirolimus and partial response to inhibition of MEK. Conclusions This clinical case illustrates the depth of investigation necessary to fully characterize the functional significance of the breadth of alterations identified through genomic analysis.